are ATX-304 and SANA proven human weight-loss drugs?
both compounds crossed into human experiments. neither has crossed into an approved, durable weight-loss evidence package.
verdict: early human signal, proven-drug claim unsupported (short trials / long-term outcomes absent)
quick answer
ATX-304 has a 28-day randomized diabetes study and a small eight-week obesity conference report. SANA has a short phase 1A/B program with exploratory weight and metabolic endpoints. Neither establishes durable weight-loss efficacy, long-term safety, or approved use.
the evidence
these are not animal-only programs. (supported)
ATX-304 reduced fasting glucose and blood pressure in a short randomized diabetes study. SANA reported early weight and glucose findings in phase 1 participants.
the human clocks are short. (gap)
A 28-day paper, an eight-week conference report, and a 15-day multiple-dose phase 1 cohort cannot establish durable obesity efficacy or chronic interaction and reproductive safety.
early safety signals remain visible. (risk)
Two of three participants at SANA's highest single exposure developed reversible renal tubular injury. ATX-304 lacks a published human terminal half-life, and its displayed 11-hour value is mouse-only and graph-derived.
bottom line
phase 1 or pilot movement is evidence, not confirmation.
scores
- human exposure: 58 — both compounds reached controlled studies
- durable weight loss: 12 — no mature long-term outcome program
- safety depth: 16 — short exposure and a high-dose renal signal
- approval: 0 — neither is approved
keep reading
- open ATX-304 entry — AMPK and early human trial
- open SANA entry — creatine thermogenesis and phase 1
- weight-loss category — approved and investigational evidence
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
